نتایج جستجو برای: interferon β
تعداد نتایج: 243008 فیلتر نتایج به سال:
1994). 4. PRISMS Study Group: Randomiseddouble-blind placebo-controlled study of interferon β-1a in relapsing/remittingmultiple sclerosis. PRISMS (Prevention ofRelapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) StudyGroup [see comments]. Lancet 352,1498–1504 (1998).5. Johnson KP, Brooks BR, Cohen JA et al.:Copolymer 1 reduces relapse rat...
BACKGROUND To further understand management of pediatric patients with multiple sclerosis (MS), we examined disease features, clinical practice patterns, and response to treatment in the United States (US) and seven other countries ('rest of World'; ROW). METHODS Anonymized data, recorded as part of routine clinical practice, were obtained from medical records (1997-2009) of study participant...
Abstract Red blood cell (RBC) transfusion can induce anti-RBC antibodies that promote hemolytic events. Patients with systemic lupus erythematosus (SLE) have an increased frequency of RBC alloimmunization, and two-thirds patients express a type 1 interferon (IFNα/β) gene signature. We previously reported IFNα/β induces alloimmunization in the IFNα/β-dependent pristane mouse model. However, it i...
Mycobacterium bovis (M. bovis) is the pathogen of animals and humans that can replicate in the phagosomes of myeloid cells. Cytosolic detection of bacterial products plays a crucial role in initiating the innate immune response, including autophagy activation and interferon-β (IFN-β) release. Although IFN-β release and autophagy activation have been reported during mycobacterium infection, the ...
BACKGROUND Methotrexate, a toxic antimetabolite that limits cellular reproduction by acting as an antagonist to folic acid, has been used to control autoimmune disease with different results. The aim of this study was to evaluate the effectiveness of low dose Methotrexate in the relapsing-remitting multiple sclerosis (RRMS). METHODS Eighty patients with definite RRMS aged 15 to 55 years were ...
OBJECTIVES To compare treatment persistence between two dosages of interferon β-1a in a large observational multiple sclerosis registry and assess disease outcomes of first line MS treatment at these dosages using propensity scoring to adjust for baseline imbalance in disease characteristics. METHODS Treatment discontinuations were evaluated in all patients within the MSBase registry who comm...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید